Management of recurrent head and neck cancer: Recent progress and future directions

Drugs

Volumn 71, Issue 12, 2011, Pages 1551-1559

  Brockstein, Bruce E ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Afatinib; Bevacizumab; Carboplatin; Cetuximab; Cisplatin; Erlotinib; Fluorouracil; Gefitinib; Head and neck cancer; Lapatinib; Lonafarnib; Methotrexate; Semaxanib; Sorafenib; Squamous cell cancer; Sunitinib; Taxanes.

Indexed keywords

AFATINIB; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; LAPATINIB; LONAFARNIB; METHOTREXATE; NAVELBINE; PACLITAXEL; SEMAXANIB; SORAFENIB; SUNITINIB; VINBLASTINE;

ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HEAD AND NECK CARCINOMA; HUMAN; MULTIPLE CYCLE TREATMENT; PAPILLOMAVIRUS INFECTION; RASH; RECURRENT CANCER; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME;

HUMAN PAPILLOMAVIRUS;

EID: 80051966802     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11592540-000000000-00000     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 CA. Cancer J Clin 2010; 60: 277-300
2. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000 CA. Cancer J Clin 2000; 50: 7-33
3. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008; 113 (10 Suppl.): 2901-9
4. Auluck A, Hislop G, Bajdik C, et al. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer 2010 Jun 1; 116 (11): 2635-44
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-90
6. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 34: 5518-23
7. Shiono S, Kawamura M, Sato T, et al., Metastatic Lung Tumor Study Group of Japan. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg 2009; 88: 856-60
8. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68: 731-40 (Pubitemid 46818729)
9. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006; 64: 382-91 (Pubitemid 43083422)
10. Tanvetyanon T, Padhya T, McCafffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009; 27: 1983-91
11. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283-9 (Pubitemid 15240980)
12. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamouscell carcinoma of the head and neck. A Southwest Oncology Group Study. J Clin Oncol 1992; 10: 1245-51
13. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-63
14. A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head andNeckOncologyGroup. Br JCancer 1990; 61: 311-5
15. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521-6 (Pubitemid 24223504)
16. Williams SD, Velez-Garcia E, Essessee I, et al. Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 1986; 57: 18-23 (Pubitemid 16212228)
17. Vogl SE, Schoenfeld DA, Kaplan BH, et al. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 1985; 56: 432-42 (Pubitemid 15035565)
18. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-7
19. Schöffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck-results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10: 119-22 (Pubitemid 29090602)
20. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 1325-30 (Pubitemid 28175747)
21. Worden FP, Moon J, Samlowski W, et al., Southwest Oncology Group, Head and NeckWorking Group. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 2006; 107: 319-27 (Pubitemid 44036561)
22. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 2000; 23: 128-31
23. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27
24. Drelichman A, Cummings G, Al-Sarraf M. A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell carcinoma of the head and neck. Cancer 1983; 52: 399-403 (Pubitemid 13073463)
25. PosnerMR, Hershock DM, Blajman CR, et al., for the TAX324 StudyGroup. Cisplatin and fluorouracil alone orwith docetaxel in head and neck cancer. N Engl JMed 2007; 357: 1705-15 (Pubitemid 350005152)
26. Vermorken JB, Remenar E, van Herpen C, et al., for the EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704 (Pubitemid 350005151)
27. Burtness B, Goldwasser MA, Flood W, et al., Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54 (Pubitemid 46211507)
28. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. JClin Oncol 2005; 23: 5578-87
29. Baselga M, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinumbased chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-77
30. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy. J Clin Oncol 2007; 25: 2171-7 (Pubitemid 46954639)
31. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7 (Pubitemid 46606387)
32. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418-24 (Pubitemid 41746956)
33. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85 (Pubitemid 41095117)
34. Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010; 28: 677-83
35. Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28: 21-8
36. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010; 65: 649-60
37. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28: 3330-5
38. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73 (Pubitemid 47372619)
39. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic squamous cell carcinoma of the head and neck [abstract]. Proc ASCO 2006; 24 (18S): 5568
40. Burris 3rd HA, Taylor CW, Jones SF, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009; 15: 6702
41. Seiwert TY, Clement PM, CupissolD, et al. BIBW2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study [abstract]. J Clin Oncol 2010; 28 Suppl. 15s: 5501
42. Fury MG, Zahalsky A, Wong R, et al. A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007; 25: 165-72 (Pubitemid 46020876)
43. Hanrahan EO, Kies MS, Glisson BS, et al. A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009; 32: 274-9
44. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-57